- Lumen Bioscience, a Seattle, WA-based clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, closed a $16m Series B financing
- The round was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital
- The funding, which brings Lumen’s total equity and non-dilutive investment to $68m
- It will also support continued advancement of the company’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea
- Lumen discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent
- Lumen also commissioned its dedicated cGMP manufacturing plant, which is currently manufacturing approximately 3 kg of drug material per week
